Driving clinical progress of gene therapy in cystic fibrosis
Cell & Gene Therapy Insights 2021; 7(7), 803–807
Published: 28 July 2021
Uta Griesenbach is a Professor in Molecular Medicine at Imperial College London, President of the British Society for Gene and Cell Therapy (www.bsgct.org/) and Director (non-excecutive) of the Celll and Gene Therapy Catapult. Uta has over 25 years experience in developing advanced therapeutic medicines. Her reserach interests are related to the development of gene and cell therapy-based treatments for cystic fibrosis and other lung diseases. As part of her translational research, Uta has overseen vector and biomarker development, toxicology studies, as well as GMP vector manufacturing. Uta is Co-Investigator on several gene therapy trials. Uta is a Strategy Group Member of the Respiratory Gene Therapy Consortium (www.cfgenetherapy.org.uk/) and a member of the MRC-DPFS panel. In addition, Uta is interested in teaching and work-force development. She is Deputy-director for post-graduate reserach at the National Heart and Lung Institute, Programme director for the MSc in Genes, Drugs and Stem cells-Novel Therapies at Imperial College and chairs the Pan-UK working group for ATMP workforce training.